Please ensure Javascript is enabled for purposes of website accessibility

President Trump Begins Treatment With Remdesivir from Gilead Sciences

By Cory Renauer – Oct 3, 2020 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The President's physicians started him on a course of treatment with an antiviral drug authorized to treat hospitalized COVID-19 patients.

On Friday evening, Dr. Sean P. Conley, President Trump's physician, sent the White House Press Secretary a health update with the permission of the President. Dr. Conley states the President's condition hasn't become severe enough to require supplemental oxygen, but he has received his second experimental antiviral treatment.

Specialists at Walter Reed National Military Medical Center have decided to begin a course of treatment with Veklury, a wide-spectrum antiviral drug from Gilead Sciences (GILD 3.82%) more commonly known by its generic name, remdesivir. 

Physician in a hospital with a clipboard.

Image source: Getty Images.

About Veklury (remdesivir)

At the moment, Veklury is authorized by the FDA for the emergency treatment of hospitalized COVID-19 patients and patients with moderate symptoms. In August, Gilead Sciences submitted a new drug application for Veklury, supported by results of a randomized, placebo-controlled study conducted by the National Institute of Allergy and Infectious Diseases (NIAID).

During the NIAID study, treatment with Veklury didn't produce evidence of a survival benefit, but it significantly reduced the amount of time COVID-19 patients spent in the hospital. A majority of patients that received remdesivir recovered in 11 days or less compared to 15 days for the placebo group. Gilead has also shown a five-day course of this intravenously delivered treatment works just as well as a 10-day course.

American hospitals have been able to purchase Veklury directly from Gilead since Oct. 1. Over the past five months, the U.S. Department of Health and Human Services has distributed enough Veklury to provide around 150,000 courses of treatment in U.S. hospitals. 

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.